Advertisement

Uveitis pp 101-142 | Cite as

Infectious Intermediate, Posterior, and Panuveitis

  • Mohsin H. Ali
  • Wenlan Zhang
  • Dilraj S. GrewalEmail author
Chapter
Part of the Current Practices in Ophthalmology book series (CUPROP)

Abstract

The aim of this chapter is to discuss the microbiology, epidemiology, clinical presentation, and updates on management of a range of commonly encountered infectious causes of intermediate, posterior, and panuveitis.

We discuss viruses including cytomegalovirus, herpes zoster and simplex virus, and West Nile virus and parasites including toxoplasmosis, toxocariasis, diffuse unilateral subacute neuroretinitis, and cysticercosis. Syphilis, tuberculosis, tick-borne disease, and fungal and infectious bacterial endophthalmitis are also described.

Keywords

Infectious uveitis Viral retinitis Toxoplasma chorioretinitis Tuberculosis Fungal endophthalmitis Presumed ocular histoplasmosis syndrome Syphilis Syphilitic uveitis Endophthalmitis Necrotizing herpetic retinopathy Lyme disease 

Notes

Acknowledgments

Conflict of Interest: No conflicting relationship exists for any author.

Financial Support: NIH Core Grant for Vision Research EY05722 and the Unrestricted RPB Grant from Research to Prevent Blindness Inc. (both to Duke University Department of Ophthalmology).

References

  1. 1.
    Staras SAS, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis. 2006;43(9):1143–51.CrossRefGoogle Scholar
  2. 2.
    Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20(4):202–13.CrossRefGoogle Scholar
  3. 3.
    Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17(4):253–76.CrossRefGoogle Scholar
  4. 4.
    Jabs DA, Van Natta ML, Thorne JE, Weinberg DV, Meredith TA, Kuppermann BD, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology. 2004;111(12):2224–31.CrossRefGoogle Scholar
  5. 5.
    Port AD, Orlin A, Kiss S, Patel S, D’Amico DJ, Gupta MP. Cytomegalovirus retinitis: a review. J Ocul Pharmacol Ther. 2017;33(4):224–34.CrossRefGoogle Scholar
  6. 6.
    Jeon S, Lee WK, Lee Y, Lee DG, Lee JW. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation. Ophthalmology. 2012;119(9):1892–8.CrossRefGoogle Scholar
  7. 7.
    Sugar EA, Jabs DA, Ahuja A, Thorne JE, Danis RP, Meinert CL, et al. Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2012;153(6):1016–1024.e5.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD, et al. Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. Ophthalmology. 2007;114(4):780–6.CrossRefGoogle Scholar
  9. 9.
    Lee JH, Agarwal A, Mahendradas P, Lee CS, Gupta V, Pavesio CE, et al. Viral posterior uveitis. Surv Ophthalmol. 2017;62(4):404–45.CrossRefGoogle Scholar
  10. 10.
    Jabs DA, Van Natta ML, Thorne JE, Weinberg DV, Meredith TA, Kuppermann BD, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology. 2004;111(12):2232–9.CrossRefGoogle Scholar
  11. 11.
    Vrabec TR. Posterior segment manifestations of HIV/AIDS. Surv Ophthalmol. 2004;49(2):131–57.CrossRefGoogle Scholar
  12. 12.
    Iu LP, Fan MC, Lau JK, Chan TS, Kwong Y-L, Wong IY. Long-term follow-up of cytomegalovirus retinitis in non-HIV immunocompromised patients: clinical features and visual prognosis. Am J Ophthalmol. 2016;165:145–53.CrossRefGoogle Scholar
  13. 13.
    Scheepers MA, Lecuona KA, Rogers G, Bunce C, Corcoran C, Michaelides M. The value of routine polymerase chain reaction analysis of intraocular fluid specimens in the diagnosis of infectious posterior uveitis. Scientific World Journal. 2013;2013:545149.CrossRefGoogle Scholar
  14. 14.
    Arevalo JF, Garcia RA, Mendoza AJ. High-dose (5000-microg) intravitreal ganciclovir combined with highly active antiretroviral therapy for cytomegalovirus retinitis in HIV-infected patients in Venezuela. Eur J Ophthalmol. 2005;15(5):610–8.CrossRefGoogle Scholar
  15. 15.
    Hoang QV, Simon DM, Kumar GN, Oh F, Goldstein DA. Recurrent CMV retinitis in a non-HIV patient with drug-resistant CMV. Graefes Arch Clin Exp Ophthalmol. 2010;248(5):737–40.CrossRefGoogle Scholar
  16. 16.
    Jabs DA, Ahuja A, Van Natta M, Lyon A, Srivastava S, Gangaputra S, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes. Ophthalmology. 2010;117(11):2152–61.e1-2CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Muthiah MN, Michaelides M, Child CS, Mitchell SM. Acute retinal necrosis: a national population-based study to assess the incidence, methods of diagnosis, treatment strategies and outcomes in the UK. Br J Ophthalmol. 2007;91(11):1452–5.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hillenkamp J, Nölle B, Bruns C, Rautenberg P, Fickenscher H, Roider J. Acute retinal necrosis: clinical features, early vitrectomy, and outcomes. Ophthalmology. 2009;116(10):1971–1975.e2.CrossRefGoogle Scholar
  19. 19.
    Lau CH, Missotten T, Salzmann J, Lightman SL. Acute retinal necrosis features, management, and outcomes. Ophthalmology. 2007;114(4):756–62.CrossRefGoogle Scholar
  20. 20.
    Ganatra JB, Chandler D, Santos C, Kuppermann B, Margolis TP. Viral causes of the acute retinal necrosis syndrome. Am J Ophthalmol. 2000;129(2):166–72.CrossRefGoogle Scholar
  21. 21.
    Cochrane TF, Silvestri G, McDowell C, Foot B, McAvoy CE. Acute retinal necrosis in the United Kingdom: results of a prospective surveillance study. Eye (Lond). 2012;26(3):370–7. quiz 378CrossRefGoogle Scholar
  22. 22.
    Holland GN. Standard diagnostic criteria for the acute retinal necrosis syndrome. Executive Committee of the American Uveitis Society. Am J Ophthalmol. 1994;117(5):663–7.CrossRefGoogle Scholar
  23. 23.
    Engstrom RE, Holland GN, Margolis TP, Muccioli C, Lindley JI, Belfort R, et al. The progressive outer retinal necrosis syndrome. A variant of necrotizing herpetic retinopathy in patients with AIDS. Ophthalmology. 1994;101(9):1488–502.CrossRefGoogle Scholar
  24. 24.
    Guex-Crosier Y, Rochat C, Herbort CP. Necrotizing herpetic retinopathies. A spectrum of herpes virus-induced diseases determined by the immune state of the host. Ocul Immunol Inflamm. 1997;5(4):259–65.CrossRefGoogle Scholar
  25. 25.
    Gariano RF, Berreen JP, Cooney EL. Progressive outer retinal necrosis and acute retinal necrosis in fellow eyes of a patient with acquired immunodeficiency syndrome. Am J Ophthalmol. 2001;132(3):421–3.CrossRefGoogle Scholar
  26. 26.
    Chawla R, Tripathy K, Gogia V, Venkatesh P. Progressive outer retinal necrosis-like retinitis in immunocompetent hosts. BMJ Case Rep. 2016;2016Google Scholar
  27. 27.
    Schoenberger SD, Kim SJ, Thorne JE, Mruthyunjaya P, Yeh S, Bakri SJ, et al. Diagnosis and treatment of acute retinal necrosis: a report by the American Academy of Ophthalmology. Ophthalmology. 2017;124(3):382–92.CrossRefGoogle Scholar
  28. 28.
    Höglund M, Ljungman P, Weller S. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother. 2001;47(6):855–61.CrossRefGoogle Scholar
  29. 29.
    Wong R, Pavesio CE, Laidlaw DAH, Williamson TH, Graham EM, Stanford MR. Acute retinal necrosis: the effects of intravitreal foscarnet and virus type on outcome. Ophthalmology. 2010;117(3):556–60.CrossRefGoogle Scholar
  30. 30.
    Yeh S, Suhler EB, Smith JR, Bruce B, Fahle G, Bailey ST, et al. Combination systemic and intravitreal antiviral therapy in the management of acute retinal necrosis syndrome. Ophthalmic Surg Lasers Imaging Retina. 2014;45(5):399–407.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Bains HS, Jampol LM, Caughron MC, Parnell JR. Vitritis and chorioretinitis in a patient with West Nile virus infection. Arch Ophthalmol. 2003;121(2):205–7.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis. 2005;11(8):1174–9.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Khairallah M, Ben Yahia S, Ladjimi A, Zeghidi H, Ben Romdhane F, Besbes L, et al. Chorioretinal involvement in patients with West Nile virus infection. Ophthalmology. 2004;111(11):2065–70.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Khairallah M, Ben Yahia S, Attia S, Zaouali S, Ladjimi A, Messaoud R. Linear pattern of West Nile virus-associated chorioretinitis is related to retinal nerve fibres organization. Eye (Lond). 2007;21(7):952–5.CrossRefGoogle Scholar
  35. 35.
    Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol. 2003;136(6):973–88.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Furtado JM, Winthrop KL, Butler NJ, Smith JR. Ocular toxoplasmosis I: parasitology, epidemiology and public health. Clin Exp Ophthalmol. 2013;41(1):82–94.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Butler NJ, Furtado JM, Winthrop KL, Smith JR. Ocular toxoplasmosis II: clinical features, pathology and management. Clin Exp Ophthalmol. 2013;41(1):95–108.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol. 2004;137(1):1–17.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Friedmann CT, Knox DL. Variations in recurrent active toxoplasmic retinochoroiditis. Arch Ophthalmol. 1969;81(4):481–93.CrossRefGoogle Scholar
  40. 40.
    Bosch-Driessen LEH, Berendschot TTJM, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology. 2002;109(5):869–78.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Elkins BS, Holland GN, Opremcak EM, Dunn JP, Jabs DA, Johnston WH, et al. Ocular toxoplasmosis misdiagnosed as cytomegalovirus retinopathy in immunocompromised patients. Ophthalmology. 1994;101(3):499–507.CrossRefGoogle Scholar
  42. 42.
    Harper TW, Miller D, Schiffman JC, Davis JL. Polymerase chain reaction analysis of aqueous and vitreous specimens in the diagnosis of posterior segment infectious uveitis. Am J Ophthalmol. 2009;147(1):140–7.e2CrossRefGoogle Scholar
  43. 43.
    Kim SJ, Scott IU, Brown GC, Brown MM, Ho AC, Ip MS, et al. Interventions for toxoplasma retinochoroiditis: a report by the American Academy of Ophthalmology. Ophthalmology. 2013;120(2):371–8.CrossRefGoogle Scholar
  44. 44.
    Schantz PM, Glickman LT. Toxocaral visceral larva migrans. N Engl J Med. 1978;298(8):436–9.CrossRefGoogle Scholar
  45. 45.
    Ahn SJ, Woo SJ, Jin Y, Chang Y-S, Kim TW, Ahn J, et al. Clinical features and course of ocular toxocariasis in adults. PLoS Negl Trop Dis. 2014;8(6):e2938.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Padhi TR, Das S, Sharma S, Rath S, Rath S, Tripathy D, et al. Ocular parasitoses: a comprehensive review. Surv Ophthalmol. 2017;62(2):161–89.CrossRefGoogle Scholar
  47. 47.
    Sabrosa NA, de Souza EC. Nematode infections of the eye: toxocariasis and diffuse unilateral subacute neuroretinitis. Curr Opin Ophthalmol. 2001;12(6):450–4.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Shields JA. Ocular toxocariasis. A review. Surv Ophthalmol. 1984;28(5):361–81.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Despreaux R, Fardeau C, Touhami S, Brasnu E, Champion E, Paris L, et al. Ocular toxocariasis: clinical features and long-term visual outcomes in adult patients. Am J Ophthalmol. 2016;166:162–8.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Wang ZJ, Zhou M, Cao WJ, Ji J, Bi YW, Huang X, et al. Evaluation of the Goldmann-Witmer coefficient in the immunological diagnosis of ocular toxocariasis. Acta Trop. 2016;158:20–3.CrossRefGoogle Scholar
  51. 51.
    Casella AMB, Farah ME, de SEC, Belfort R, Oguido APMT. Retinal nerve fiber layer atrophy as relevant feature for diffuse unilateral subacute neuroretinitis (DUSN): case series. Arq Bras Oftalmol. 2010;73(2):182–5.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Gass JD, Braunstein RA. Further observations concerning the diffuse unilateral subacute neuroretinitis syndrome. Arch Ophthalmol. 1983;101(11):1689–97.CrossRefGoogle Scholar
  53. 53.
    Dhiman R, Devi S, Duraipandi K, Chandra P, Vanathi M, Tandon R, et al. Cysticercosis of the eye. Int J Ophthalmol. 2017;10(8):1319–24.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Ganesh SK, Priyanka. Analysis of clinical profile, investigation, and management of ocular cysticercosis seen at a tertiary referral Centre. Ocul Immunol Inflamm. 2018;26:1–8.CrossRefGoogle Scholar
  55. 55.
    Syphilis [Internet]. Center for Disease Control and Prevention; 2017. Available from: https://www.cdc.gov/std/stats16/syphilis.htm
  56. 56.
    Kiss S, Damico FM, Young LH. Ocular manifestations and treatment of syphilis. Semin Ophthalmol. 2005;20(3):161–7.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Aldave AJ, King JA, Cunningham ET. Ocular syphilis. Curr Opin Ophthalmol. 2001;12(6):433–41.CrossRefGoogle Scholar
  58. 58.
    Golden MR, Marra CM, Holmes KK. Update on syphilis: resurgence of an old problem. JAMA. 2003;290(11):1510–4.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Browning DJ. Posterior segment manifestations of active ocular syphilis, their response to a neurosyphilis regimen of penicillin therapy, and the influence of human immunodeficiency virus status on response. Ophthalmology. 2000;107(11):2015–23.CrossRefGoogle Scholar
  60. 60.
    Hoogewoud F, Frumholtz L, Loubet P, Charlier C, Blanche P, Lebeaux D, et al. Prognostic factors in syphilitic uveitis. Ophthalmology. 2017;124(12):1808–16.CrossRefGoogle Scholar
  61. 61.
    Moradi A, Salek S, Daniel E, Gangaputra S, Ostheimer TA, Burkholder BM, et al. Clinical features and incidence rates of ocular complications in patients with ocular syphilis. Am J Ophthalmol. 2015;159(2):334–43.e1CrossRefGoogle Scholar
  62. 62.
    Villanueva AV, Sahouri MJ, Ormerod LD, Puklin JE, Reyes MP. Posterior uveitis in patients with positive serology for syphilis. Clin Infect Dis. 2000;30(3):479–85.CrossRefGoogle Scholar
  63. 63.
    Bakhsh SR, Ali MH, Bhat P. Chorioretinal lesions and symptoms of elevated intracranial pressure. JAMA Ophthalmol. 2017;135(8):889–90.CrossRefGoogle Scholar
  64. 64.
    Gass JD, Braunstein RA, Chenoweth RG. Acute syphilitic posterior placoid chorioretinitis. Ophthalmology. 1990;97(10):1288–97.CrossRefGoogle Scholar
  65. 65.
    Eandi CM, Neri P, Adelman RA, Yannuzzi LA, Cunningham ET, International Syphilis Study Group. Acute syphilitic posterior placoid chorioretinitis: report of a case series and comprehensive review of the literature. Retina. 2012;32(9):1915–41.CrossRefGoogle Scholar
  66. 66.
    Pichi F, Ciardella AP, Cunningham ET, Morara M, Veronese C, Jumper JM, et al. Spectral domain optical coherence tomography findings in patients with acute syphilitic posterior placoid chorioretinopathy. Retina. 2014;34(2):373–84.CrossRefGoogle Scholar
  67. 67.
    Dunseth CD, Ford BA, Krasowski MD. Traditional versus reverse syphilis algorithms: a comparison at a large academic medical center. Pract Lab Med. 2017;8:52–9.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Gupta V, Gupta A, Rao NA. Intraocular tuberculosis – an update. Surv Ophthalmol. 2007;52(6):561–87.CrossRefGoogle Scholar
  69. 69.
    World Health Organization. Global tuberculosis report 2017. S.l.: World Health Organization; 2017.Google Scholar
  70. 70.
    Raja H, Starr MR, Bakri SJ. Ocular manifestations of tick-borne diseases. Surv Ophthalmol. 2016;61(6):726–44.CrossRefGoogle Scholar
  71. 71.
    Sathiamoorthi S, Smith WM. The eye and tick-borne disease in the United States. Curr Opin Ophthalmol. 2016;27(6):530–7.CrossRefGoogle Scholar
  72. 72.
    Vannier E, Krause PJ. Human babesiosis. N Engl J Med. 2012;366(25):2397–407.CrossRefGoogle Scholar
  73. 73.
    Romero JR, Simonsen KA. Powassan encephalitis and Colorado tick fever. Infect Dis Clin N Am. 2008;22(3):545–59, xCrossRefGoogle Scholar
  74. 74.
    McFee RB, Bush L, Vazquez-Pertejo MT. Tick borne illness—Rocky mountain spotted fever. Dis Mon. 2018;64(5):185–94.CrossRefGoogle Scholar
  75. 75.
    Relhan N, Forster RK, Flynn HW. Endophthalmitis: then and now. Am J Ophthalmol. 2018;187:xx–xxvii.CrossRefGoogle Scholar
  76. 76.
    Patel AV, Young LH. Endogenous endophthalmitis. In: Durand M, Miller J, Young L, editors. Endophthalmitis. New York, NY: Springer; 2016.Google Scholar
  77. 77.
    Jackson TL, Paraskevopoulos T, Georgalas I. Systematic review of 342 cases of endogenous bacterial endophthalmitis. Surv Ophthalmol. 2014;59(6):627–35.CrossRefGoogle Scholar
  78. 78.
    Jackson TL, Eykyn SJ, Graham EM, Stanford MR. Endogenous bacterial endophthalmitis: a 17-year prospective series and review of 267 reported cases. Surv Ophthalmol. 2003;48(4):403–23.CrossRefGoogle Scholar
  79. 79.
    Gregori NZ, Flynn HW, Schwartz SG, Rosenfeld PJ, Vaziri K, Moshfeghi AA, et al. Current infectious endophthalmitis rates after intravitreal injections of anti-vascular endothelial growth factor agents and outcomes of treatment. Ophthalmic Surg Lasers Imaging Retina. 2015;46(6):643–8.CrossRefGoogle Scholar
  80. 80.
    Avery RL, Bakri SJ, Blumenkranz MS, Brucker AJ, Cunningham ET, DʼAmico DJ, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34(Suppl 12):S1–18.CrossRefGoogle Scholar
  81. 81.
    Cao H, Zhang L, Li L, Lo S. Risk factors for acute endophthalmitis following cataract surgery: a systematic review and meta-analysis. PLoS One. 2013;8(8):e71731.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Rahmani S, Eliott D. Postoperative Endophthalmitis: a review of risk factors, prophylaxis, incidence, microbiology, treatment, and outcomes. Semin Ophthalmol. 2018;33(1):95–101.CrossRefGoogle Scholar
  83. 83.
    Gower EW, Lindsley K, Tulenko SE, Nanji AA, Leyngold I, McDonnell PJ. Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery. Cochrane Database Syst Rev. 2017;2:CD006364.Google Scholar
  84. 84.
    Haripriya A, Chang DF, Ravindran RD. Endophthalmitis reduction with Intracameral Moxifloxacin prophylaxis: analysis of 600 000 surgeries. Ophthalmology. 2017;124(6):768–75.CrossRefGoogle Scholar
  85. 85.
    Jabbarvand M, Hashemian H, Khodaparast M, Jouhari M, Tabatabaei A, Rezaei S. Endophthalmitis occurring after cataract surgery: outcomes of more than 480 000 cataract surgeries, epidemiologic features, and risk factors. Ophthalmology. 2016;123(2):295–301.CrossRefGoogle Scholar
  86. 86.
    Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33(6):978–88.CrossRefGoogle Scholar
  87. 87.
    Creuzot-Garcher C, Benzenine E, Mariet A-S, de Lazzer A, Chiquet C, Bron AM, et al. Incidence of acute postoperative Endophthalmitis after cataract surgery: a Nationwide study in France from 2005 to 2014. Ophthalmology. 2016;123(7):1414–20.CrossRefGoogle Scholar
  88. 88.
    Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 1996;122(1):1–17.CrossRefGoogle Scholar
  89. 89.
    Vaziri K, Kishor K, Schwartz SG, Maharaj AS, Moshfeghi DM, Moshfeghi AA, et al. Incidence of bleb-associated endophthalmitis in the United States. Clin Ophthalmol. 2015;9:317–22.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Zheng CX, Moster MR, Khan MA, Chiang A, Garg SJ, Dai Y, et al. Infectious endophthalmitis after glaucoma drainage implant surgery: clinical features, microbial spectrum, and outcomes. Retina. 2017;37(6):1160–7.CrossRefGoogle Scholar
  91. 91.
    Park JC, Ramasamy B, Shaw S, Prasad S, Ling RHL. A prospective and nationwide study investigating endophthalmitis following pars plana vitrectomy: incidence and risk factors. Br J Ophthalmol. 2014;98(4):529–33.CrossRefGoogle Scholar
  92. 92.
    Clarke B, Williamson T, Gini G, Gupta B. Management of bacterial postoperative endophthalmitis and the role of vitrectomy. Surv Ophthalmol. 2018;63(5):677–93.CrossRefGoogle Scholar
  93. 93.
    Kim CH, Chen MF, Coleman AL. Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure. Cochrane Database Syst Rev. 2017;2:CD012131.Google Scholar
  94. 94.
    Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Results of the Endophthalmitis Vitrectomy study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol. 1995;113(12):1479–96.CrossRefGoogle Scholar
  95. 95.
    Shah CP, McKey J, Spirn MJ, Maguire J. Ocular candidiasis: a review. Br J Ophthalmol. 2008;92(4):466–8.CrossRefGoogle Scholar
  96. 96.
    Adam MK, Vahedi S, Nichols MM, Fintelmann RE, Keenan JD, Garg SJ, et al. Inpatient ophthalmology consultation for Fungemia: prevalence of ocular involvement and necessity of Funduscopic screening. Am J Ophthalmol. 2015;160(5):1078–83.e2CrossRefGoogle Scholar
  97. 97.
    Vinikoor MJ, Zoghby J, Cohen KL, Tucker JD. Do all candidemic patients need an ophthalmic examination? Int J Infect Dis. 2013;17(3):e146–8.CrossRefGoogle Scholar
  98. 98.
    Oude Lashof AML, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, et al. Ocular manifestations of candidemia. Clin Infect Dis. 2011;53(3):262–8.CrossRefGoogle Scholar
  99. 99.
    Khalid A, Clough LA, Symons RCA, Mahnken JD, Dong L, Eid AJ. Incidence and clinical predictors of ocular candidiasis in patients with Candida fungemia. Interdiscip Perspect Infect Dis. 2014;2014:650235.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Dozier CC, Tarantola RM, Jiramongkolchai K, Donahue SP. Fungal eye disease at a tertiary care center: the utility of routine inpatient consultation. Ophthalmology. 2011;118(8):1671–6.CrossRefGoogle Scholar
  101. 101.
    Diaz RI, Sigler EJ, Rafieetary MR, Calzada JI. Ocular histoplasmosis syndrome. Surv Ophthalmol. 2015;60(4):279–95.CrossRefGoogle Scholar
  102. 102.
    Thuruthumaly C, Yee DC, Rao PK. Presumed ocular histoplasmosis. Curr Opin Ophthalmol. 2014;25(6):508–12.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Mohsin H. Ali
    • 1
  • Wenlan Zhang
    • 1
  • Dilraj S. Grewal
    • 1
    Email author
  1. 1.Department of OphthalmologyDuke UniversityDurhamUSA

Personalised recommendations